Evaluation of Safety and Reduction of Ear Pain in Adults With Acute Otitis Media and Reduction of Ear Pain in Adults With Acute Otitis Media



Status:Completed
Conditions:Other Indications, Infectious Disease, Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases, Other
Healthy:No
Age Range:18 - Any
Updated:3/1/2019
Start Date:January 7, 2019
End Date:January 30, 2019

Use our guide to learn which trials are right for you!

Evaluation of Safety and Reduction of Ear Pain in Adults With Acute Otitis Media

The purpose of this study is to evaluate the Safety and Reduction of Ear Pain in Adults with
Acute Otitis Media.


Inclusion Criteria includes but is not limited to:

1. AOM diagnosis with moderate to severe bulging of the TM and recent (< 48 hours [h])
onset of ear pain.

2. Moderate to severe ear pain in the affected ear(s), defined as a score of ≥ 5 (on a
scale of 0 10) on the NRS 11 as evaluated by the subject at Screening.

3. Generally good health (other than AOM) as determined by evaluation of medical history
and physical examination at Screening.

4. Negative urine pregnancy test at Screening for all female subjects of childbearing
potential.

5. Able to read and sign written informed consent prior to study participation.

Exclusion Criteria includes but is not limited to:

1. Presence of a perforated TM at Screening or had a perforated TM within 6 months (mo)
prior to Screening as determined by medical history

2. Subjects with tympanostomy tubes

3. Acute or chronic otitis externa

4. Chronic otitis media defined as confirmed presence of middle ear effusion for 12 weeks
or longer

5. Disorders with decreased mucociliary clearance or higher viscosity of the mucous (eg,
cystic fibrosis, primary ciliary dyskinesia, Kartagener's syndrome)

6. Clinically relevant blockage of 1 or both nasal passages, as determined by the
investigator's medical judgment

7. Permanent hearing loss irrespective of otitis media

8. Subjects with medical conditions that may affect interpretation of the safety or
efficacy of study drug as determined by the investigator's medical judgment

9. Subjects with craniofacial abnormalities (eg, cleft palate, Down's Syndrome)

10. Subjects with erythema of the TM without other evidence of otitis media

11. Seborrheic dermatitis involving the affected external ear canal or pinna

12. Use of medications with known vasoconstrictive properties (eg, decongestants [Afrin®,
Sudafed®]) currently or within 2 h prior to Screening

13. Use of oral analgesics < 2 h prior to Screening or Baseline (oral analgesics > 2 h are
permitted as long as ear pain criteria are met per Inclusion Criteria)
We found this trial at
3
sites
Miami, Florida 33176
Principal Investigator: Antonio Blanco
?
mi
from
Miami, FL
Click here to add this to my saved trials
Bellflower, California 90706
Principal Investigator: Robert Eyzaguirre
Phone: 5629206070
?
mi
from
Bellflower, CA
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Principal Investigator: Ana Kim
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials